[PDF][PDF] From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies

L Crotti, P Brugada, H Calkins, P Chevalier, G Conte… - Europace, 2023 - academic.oup.com
In the early nineties, few years before the birth of Europace, the clinical and scientific world
of familial arrhythmogenic conditions was revolutionized by the identification of the first …

Molecular basis of inflammation in the pathogenesis of cardiomyopathies

E Monda, G Palmiero, M Rubino, F Verrillo… - International Journal of …, 2020 - mdpi.com
Cardiomyopathies (CMPs) represent a diverse group of heart muscle diseases, grouped into
specific morphological and functional phenotypes. CMPs are associated with mutations in …

JCS/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies

H Kitaoka, H Tsutsui, T Kubo, T Ide, T Chikamori… - Circulation …, 2021 - jstage.jst.go.jp
The classes of recommendations and levels of evidence in these guidelines were
determined and described according to the “Guidelines for the treatment of acute and …

Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy

C Fumagalli, N Maurizi, SM Day, EA Ashley… - JAMA …, 2020 - jamanetwork.com
Importance Patients with hypertrophic cardiomyopathy (HCM) are prone to body weight
increase and obesity. Whether this predisposes these individuals to long-term adverse …

Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy

LA Eberly, SM Day, EA Ashley, DL Jacoby… - JAMA …, 2020 - jamanetwork.com
Importance Racial differences are recognized in multiple cardiovascular parameters,
including left ventricular hypertrophy and heart failure, which are 2 major manifestations of …

Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments

I Olivotto, JE Udelson, M Pieroni… - European Heart …, 2023 - academic.oup.com
Heart failure with preserved ejection fraction (HFpEF) is a major driver of cardiac morbidity
and mortality in developed countries, due to ageing populations and the increasing …

[HTML][HTML] Гипертрофическая кардиомиопатия. Клинические рекомендации 2020

СА Габрусенко, АЯ Гудкова… - Российский …, 2021 - cyberleninka.ru
Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy

R Coppini, L Santini, I Olivotto… - Cardiovascular …, 2020 - academic.oup.com
Hypertrophic cardiomyopathy (HCM) is a common inherited monogenic disease with a
prevalence of 1/500 in the general population, representing an important cause of …

Emerging medical treatment for hypertrophic cardiomyopathy

A Argirò, M Zampieri, M Berteotti, A Marchi… - Journal of clinical …, 2021 - mdpi.com
Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by
otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms …

Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy: JACC Focus Seminar 6/9

NAB Ntusi, K Sliwa - Journal of the American College of Cardiology, 2021 - jacc.org
Significant racial and ethnicity-based disparities in clinical presentation, management, and
outcome of hypertrophic cardiomyopathy (HCM) are reported. Black patients with HCM are …